White label – Pompe disease - ClinicalTrials.eu

Study on the Safety of Tenofovir Alafenamide and Natalizumab for People with Multiple Sclerosis

Not recruiting

2 1 1
Investigated Diseases:
- Multiple sclerosis
Investigated Drugs:
- Natalizumab
- Tenofovir Alafenamide
Study on Galcanezumab for Preventing Chronic Migraine in Adolescents Aged 12 to 17

Not recruiting

3 1
Investigated Drugs:
- Galcanezumab
Study on Galcanezumab for Preventing Episodic Migraine in Children and Teens Aged 6 to 17

Not recruiting

3 1
Investigated Drugs:
- Galcanezumab
Study of Ravulizumab for Children with Thrombotic Microangiopathy After Stem Cell Transplant

Not recruiting

3 1 1 1
Investigated Drugs:
- Ravulizumab
Study on the Effectiveness and Safety of Follitropin Delta for Men with Unexplained Infertility

Not recruiting

2 1 1
Investigated Diseases:
- Infertility male
Investigated Drugs:
- Follitropin Delta
Study on the Effectiveness and Safety of High-Dose Rifampicin, Moxifloxacin, and Linezolid for Patients with Pulmonary Tuberculosis

Not recruiting

2 1 1 1
Investigated Diseases:
- Pulmonary tuberculosis
Investigated Drugs:
Study on Botulinum Toxin Type A for Preventing Episodic Migraine in Adults

Not recruiting

3 1 1
Investigated Diseases:
- Migraine
Investigated Drugs:
- Botulinum Toxin Type A – Haemagglutinin Complex
Study on Triple Negative Breast Cancer Treatment with Chemotherapy, Fasting-Mimicking Diet, and Metformin for Preoperative Patients

Not recruiting

2 1 1 1
Investigated Diseases:
- Triple negative breast cancer
Investigated Drugs:
- Metformin Hydrochloride
Study of Durvalumab and Tremelimumab with Y-90 SIRT Therapy for Patients with Advanced Intrahepatic Biliary Tract Cancer

Not recruiting

2 1 1 1
Investigated Diseases:
- Cholangiocarcinoma
Investigated Drugs:
- Tremelimumab
- Durvalumab
Study on JDQ443 for Patients with KRAS G12C+ Non-Small Cell Lung Cancer and Brain Metastases

Not recruiting

2 1 1
Investigated Diseases:
Investigated Drugs:
- 1-{6-[(4M)-4-(5-Chloro-6-Methyl-1H -Indazol-4-Yl)-5-Methyl-3-(1-Methyl-1H -Indazol-5-Yl)-1H -Pyrazol-1-Yl]-2-Azaspiro[3.3]Heptan-2-Yl}Prop-2-En-1-One

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies